Navigation Links
Halozyme Therapeutics to Host Research Day for Investors and Analysts
Date:10/1/2008

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a Research Day on Wednesday, October 8, beginning at 12:15 p.m. EDT. A webcast of the presentations will be available live on the company website.

PRESENTATIONS

-- Strategic Company Overview, Jonathan Lim, M.D., President and Chief Executive Officer

-- Science and Technology Overview, Gregory Frost, Ph.D., Vice President and Chief Scientific Officer

-- Insulins -- Faster Acting, Regular and Analog, Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development

-- Bisphosphonates -- Advantages of Subcutaneous Injection with rHuPH20, Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development

-- PEGPH20 -- A Targeted Therapy for Cancer Treatment, Patrick O'Connor, Ph.D., Vice President, Research

-- Chemophase -- Next Steps to Pivotal Trials, Richard C. Yocum, M.D., Vice President, Clinical Development and Medical Affairs

-- Commercial Opportunities -- The Value Proposition, Robert L. Little, Vice President and Chief Commercial Officer

Halozyme will conduct a live webcast of the presentations beginning at 12:15 p.m. EDT. To access the webcast over the internet, please go to the company website at http://www.halozyme.com. An archive of the presentation will be available on Halozyme's website shortly after the conclusion of the meeting.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact Media Contacts

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Mentus

Investor Relations (858) 455-5500, x275/x215

(858) 704-8264 karen@mentus.com

ruhl@halozyme.com jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
6. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
7. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
11. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
Breaking Biology Technology:
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):